Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prop 65 Trace Contaminant Draft Rule Goes Over Like Lead Balloon

This article was originally published in The Tan Sheet

Executive Summary

Industry groups suggest California's proposal to lower Prop 65’s safe harbor for lead would increase litigation, consumer confusion and lead levels in products sold in the state. Stakeholders question the science behind the proposal and the timeframe allotted to consider the "highly technical" material.

You may also be interested in...



Prop 65 Limits Point Downward For Lead, Other Reprotoxic Chemicals

California issues a pre-regulatory draft rule to amend Prop 65 with a 60% lower maximum allowable dose level for lead in personal care products sold without exposure warnings. The proposal also clarifies that MADLs for listed chemicals are single-day limits, a change that could trigger new warnings and lawsuits.

FDA Issues Final Lead-In-Lipstick Report, Postpones Decision On Cosmetic Lead Limits

FDA’s expanded survey of lead levels in lipstick examined 400 products on the market, finding an average amount of 1.11 ppm, comparable with its initial test of 20 lipsticks, which averaged 1.07 ppm lead content.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel